NCT04262466 2026-03-06
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
Immunocore Ltd
Phase 1/2 Active not recruiting
Immunocore Ltd
Immunocore Ltd
H. Lee Moffitt Cancer Center and Research Institute
Roswell Park Cancer Institute
Stanford University
Ohio State University Comprehensive Cancer Center
Chugai Pharmaceutical